Guest guest Posted March 4, 2010 Report Share Posted March 4, 2010  de_la_sengle http://www.terrapinn.com/2010/asiaflu/programme.stm Friday, 11 June 2010 8am Registration and refreshments 9am Chairman opening remarks KEY DRIVERS FOR ASIA’S INFLUENZA VACCINE BUSINESS 9.05am The need for improved influenza prevention: A public health and industrial perspective Developing better influenza vaccines for improved influenza prevention Defining the role of the public health community to improve influenza control and prevention Emphasizing the role the industry can play in supporting and strengthening influenza pandemic preparedness Dr Bram Palache, Global Scientific Communication and Public Affairs Director for Influenza Vaccines, Solvay Biologicals BV 9.35am Discussing the current and future challenges for influenza Defining the burden of disease Assessing future pandemic threats in the region Pathogenesis: the virus-host interaction Prof Malik Peiris, Chair Professor of Microbiology at The University of Hong Kong, Virologist at the Queen Mary Hospital and the Scientific Director, HKU-Pasteur Research Centre at Hong Kong 10.05am Analyzing and forecasting Asia’s influenza vaccine market to effectively address the region’s evolving needs Determining the right strategies in predicting the regions demand and supply requirement for pandemic and seasonal flu vaccine Identifying the main drivers and resistors in effectively addressing Asia’s influenza market Developing a strategy for the control and pandemic preparedness Dr Mark Simmerman, Chief Epidemiologist, Influenza Section, U.S. CDC Southeast Asia Regional Office 10.35am Morning refreshment NEWLY IMPROVED INFLUENZA VACCINES 11.15am Cell culture based influenza vaccine as the next generation influenza vaccine Addressing clear important regulatory hurdles for broader licensure of cell culture based influenza vaccine Looking at the cell lines derived products having a strong safety record with the traditional egg-based products Considering the final yields and costs of the cell-based vaccines as compared with the egg-based Dr Hartmut Ehrlich, Vice President, Global R & D, Baxter BioScience 11.45am Developing universal cross-protective influenza virus vaccines Impact of different methods of whole virus inactivation on vaccine efficacy Demonstration of complete heterotypic protection in animal models Possibilities for novel avian and human influenza vaccine development in Asia Prof Tim Hirst, Executive Chairman, Gamma Vaccines 12.15pm Development challenges for a synthetic universal influenza vaccine entering the clinical phase Depo vaccine and high density antigen technology platforms underpinning the synthetic universal vaccine Assessing various development pathway for a synthetic universal influenza vaccine Targeting market needs for both seasonal and pandemic flu market segments 12.30pm Networking lunch IS ASIA PANDEMIC READY? 2pm Use of live attenuated influenza vaccine for pandemic influenza The benefits of live attenuated influenza vaccine for emerging pandemic strains Case study of LAIV development for the 2009 H1N1 pandemic Future development of LAIV in support of pandemic preparedness Dr Filip Dubovsky, Vice President Clinical Development, Therapeutic Area Head, Vaccines, Medimmune, Inc 2.30pm Discussing the latest developments of the H1N1 vaccine Presentation of the clinical trials results of H1N1 vaccine Accelerating the development of H1N1 vaccine to address the growing demand Addressing the safety concerns of the vaccine through stringent testing and evaluation Prof Nikolai Petrovsky, Chairman, Vaxine 3pm Strategies to face the challenges of delivering broadly effective pandemic vaccines at the right place and at the right moment Lessons learned from the 2009 pandemic Cost-effective strategies for global vaccine delivery Plant-based vaccines as first responder solution Clinical data from plant-derived VLP-based H5N1 vaccine Dr Andy Sheldon, President and Chief Executive Officer, Medicago 3.30pm Successful case study of H1N1 vaccine development and preparedness in Korea Presenting H1N1 vaccine production Discussing the clinical trials approvals process Establishing vaccination program in Korea Dr BG Rhee, President, Green Cross Company 4pm Afternoon refreshment 4.30pm Roundtable discussion This round table discussion session is an open moderated session where delegates are divided into groups to discuss a set or topics. This session aims to address the issues, problems and ideas of each delegate. Moderated by key industry experts, the round table discussion will ensure debate and discussion on thought-provoking and controversial issues with industry peers. 4.30pm Roundtable 1: Investigation various options to control influenza Developing an influenza pandemic preparedness plan is a must. Planning for a pandemic response program requires a global perspective and concerted effort. Various stakeholders have to work together to devise a strategy in order to make Asia pandemic ready. What are the necessary joint efforts to make prevention of new influenza pandemic possible? What are the different approaches in preventing a pandemic? How Asia pro-actively respond to an eventual pandemic? 4.30pm Roundtable 2: Meeting demand with sufficient influenza vaccine supply in Asia Balancing the demand and supply of influenza vaccine is tough especially when a pandemic strikes. Careful planning is necessary in order to predict the possible market demand in each region. Timely production of the vaccine is one concern but then next challenge is how fast can you bring it to market. What are the various ways to reduce production time and at the same time increase speed to market? Are there new manufacturing innovations that have made a big difference in the influenza vaccine industry? 5.10pm Chairman’s closing remarks 5.20pm End of conference Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.